Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

June 22, 2026

Study Completion Date

June 22, 2026

Conditions

Breast Cancer

Interventions

DIETARY_SUPPLEMENT

omega 3 fatty acids

supplied as soft gelatin capsules for oral administration

Trial Locations (2)

The Ohio State University Comprehensive Cancer Center, Columbus

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02295059 - Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention | Biotech Hunter | Biotech Hunter